A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or both

Trial Profile

A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or both

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2016

At a glance

  • Drugs Finerenone (Primary) ; Eplerenone
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms FINESSE-HF
  • Sponsors Bayer
  • Most Recent Events

    • 22 Jul 2016 The trial was prematurely ended in Belgium (end date: 11 Mar 2016).
    • 21 Jul 2016 This trial was discontinued in Netherlands.
    • 03 Jun 2016 The trial was prematurely ended in Greece (end date: 11 Mar 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top